Comparing Compass Therapeutics (NASDAQ:CMPX) and Evaxion Biotech A/S (NASDAQ:EVAX)

Compass Therapeutics (NASDAQ:CMPX) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, dividends, analyst recommendations, risk, institutional ownership, earnings and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Compass Therapeutics and Evaxion Biotech A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	0	0	2	0	3.00
Evaxion Biotech A/S	0	0	2	0	3.00

Compass Therapeutics presently has a consensus target price of $9.00, indicating a potential upside of 504.03%. Evaxion Biotech A/S has a consensus target price of $11.00, indicating a potential upside of 160.66%. Given Compass Therapeutics’ higher probable upside, research analysts plainly believe Compass Therapeutics is more favorable than Evaxion Biotech A/S.

Risk & Volatility

Compass Therapeutics has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Evaxion Biotech A/S has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.

Institutional and Insider Ownership

68.4% of Compass Therapeutics shares are held by institutional investors. Comparatively, 11.0% of Evaxion Biotech A/S shares are held by institutional investors. 30.0% of Compass Therapeutics shares are held by insiders. Comparatively, 41.6% of Evaxion Biotech A/S shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Compass Therapeutics and Evaxion Biotech A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-26.07%	-24.49%
Evaxion Biotech A/S	N/A	-451.63%	-149.27%

Valuation and Earnings

This table compares Compass Therapeutics and Evaxion Biotech A/S’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	N/A	N/A	-$42.49 million	($0.34)	-4.38
Evaxion Biotech A/S	$70,000.00	314.69	-$22.12 million	($6.76)	-0.62

Evaxion Biotech A/S has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.

Summary

Compass Therapeutics beats Evaxion Biotech A/S on 6 of the 10 factors compared between the two stocks.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.